One patient was exposed to a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (lovastatin), and one patient was exposed to ezetimibe prior to the diagnosis of IBM. This evidence concerns the gene HMGCR and inclusion body myositis.